Logo

Adaptive Biotechnologies: Mark Adams, Jyoti Palaniappan, Thomas Snyder

Apr 10, 2020

Adaptive Biotechnologies has appointed Mark Adams as chief technical officer, Jyoti Palaniappan as senior vice president of clinical diagnostics for the ImmunoSeq Dx program, and Thomas Snyder as vice president of research, ImmunoSeq Dx.

Adams has been involved in the strategy, design, and implementation of large-scale bioinformatics and data analytics programs for companies including SVB Leerink, Celmatix, Good Start Genetics, and Variagenics. He holds a PhD in cell biology from Baylor College of Medicine and completed his postdoc in computational biology at Boston University. He assumes the CTO role from Sean Nolan, who will fill a newly created role of distinguished engineer.

Palaniappan previously served as chief commercial officer for Bigfoot Biomedical. He also spent 11 years in Abbott's diabetes care business. Prior to Abbott he led global and US commercial organizations for Thermo Fisher Scientific, and provided strategic consulting services at McKinsey & Company. He holds an MBA/MPH from Emory University.

Snyder returns to Adaptive after five years as head of computational biology at Verily (formerly Google Life Sciences).

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.